Published in J Clin Virol on December 01, 2013
Ending the HIV Epidemic Through Point-of-Care Technologies (EHPOC) (EHPOC) | NCT04793750
Arguments for and against HIV self-testing. HIV AIDS (Auckl) (2014) 1.01
Multi-centre evaluation of the Determine HIV Combo assay when used for point of care testing in a high risk clinic-based population. PLoS One (2014) 0.98
Associations of sexually transmitted infections with condom problems among young men who have sex with men. Sex Transm Dis (2014) 0.87
Acceptability of using electronic vending machines to deliver oral rapid HIV self-testing kits: a qualitative study. PLoS One (2014) 0.85
Identifying Barriers to Human Immunodeficiency Virus Testing for Men Who Have Sex with Men in South Korea. Osong Public Health Res Perspect (2015) 0.84
Response to the modeling analysis by Katz et al. on the impact of replacing clinic-based HIV tests with home testing among men who have sex with men in Seattle: authors' reply. Sex Transm Dis (2014) 0.83
Evaluation of a Rapid Point of Care Test for Detecting Acute and Established HIV Infection, and Examining the Role of Study Quality on Diagnostic Accuracy: A Bayesian Meta-Analysis. PLoS One (2016) 0.83
Rationale and design of FORTH: a randomised controlled trial assessing the effectiveness of HIV self-testing in increasing HIV testing frequency among gay and bisexual men. BMC Infect Dis (2015) 0.79
Performance of Determine Combo and other point-of-care HIV tests among Seattle MSM. J Clin Virol (2016) 0.77
Field accuracy of fourth-generation rapid diagnostic tests for acute HIV-1: a systematic review. AIDS (2015) 0.77
Using a Multitest Algorithm to Improve the Positive Predictive Value of Rapid HIV Testing and Linkage to HIV Care in Nonclinical HIV Test Sites. J Acquir Immune Defic Syndr (2016) 0.75
Application of Oral Fluid Assays in Support of Mumps, Rubella and Varicella Control Programs. Vaccines (Basel) (2015) 0.75
Evaluation of the performances of six commercial kits designed for dengue NS1 and anti-dengue IgM, IgG and IgA detection in urine and saliva clinical specimens. BMC Infect Dis (2016) 0.75
Quantification of plasma HIV RNA using chemically engineered peptide nucleic acids. Nat Commun (2014) 0.75
Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis (2005) 21.08
Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS (2003) 11.66
Head-to-head comparison of accuracy of a rapid point-of-care HIV test with oral versus whole-blood specimens: a systematic review and meta-analysis. Lancet Infect Dis (2012) 3.92
Targeted screening for primary HIV infection through pooled HIV-RNA testing in men who have sex with men. AIDS (2005) 3.40
HIV transmission rates from persons living with HIV who are aware and unaware of their infection. AIDS (2012) 2.63
Choosing HIV Counseling and Testing Strategies for Outreach Settings: A Randomized Trial. J Acquir Immune Defic Syndr (2005) 2.36
A meta-analysis of the effectiveness of alternative HIV counseling and testing methods to increase knowledge of HIV status. AIDS (2006) 2.34
Detecting acute human immunodeficiency virus infection using 3 different screening immunoassays and nucleic acid amplification testing for human immunodeficiency virus RNA, 2006-2008. Arch Intern Med (2010) 2.28
HIV testing in a high-incidence population: is antibody testing alone good enough? Clin Infect Dis (2009) 2.23
Assessment of the ability of a fourth-generation immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen to detect both acute and recent HIV infections in a high-risk setting. J Clin Microbiol (2009) 2.18
Sensitivity of five rapid HIV tests on oral fluid or finger-stick whole blood: a real-time comparison in a healthcare setting. PLoS One (2010) 2.10
Alternative algorithms for human immunodeficiency virus infection diagnosis using tests that are licensed in the United States. J Clin Microbiol (2008) 1.97
False-positive oral fluid rapid HIV tests--New York City, 2005-2008. MMWR Morb Mortal Wkly Rep (2008) 1.94
Evaluation of the performance characteristics of 6 rapid HIV antibody tests. Clin Infect Dis (2011) 1.69
Evaluation of an alternative HIV diagnostic algorithm using specimens from seroconversion panels and persons with established HIV infections. J Clin Virol (2011) 1.66
Screening for acute HIV infection: lessons learned. Clin Infect Dis (2006) 1.31
Assessment of rapid tests for detection of human immunodeficiency virus-specific antibodies in recently infected individuals. J Clin Microbiol (2008) 1.26
Australian men who have sex with men prefer rapid oral HIV testing over conventional blood testing for HIV. Int J STD AIDS (2010) 1.17
HIV intertest interval among MSM in King County, Washington. Sex Transm Infect (2012) 1.07
Comparative evaluation of eight commercial enzyme linked immunosorbent assays and 14 simple assays for detection of antibodies to HIV. J Virol Methods (2002) 1.06
ru2hot?: A public health education campaign for men who have sex with men to increase awareness of symptoms of acute HIV infection. Sex Transm Infect (2013) 1.05
Comparison of the sensitivity of four rapid assays for the detection of antibodies to HIV-1/HIV-2 during seroconversion. Clin Diagn Virol (1996) 1.05
Negative rapid HIV antibody testing during early HIV infection. Ann Intern Med (2007) 1.03
Sensitivity and specificity of standard and rapid HIV-antibody tests evaluated by seroconversion and non-seroconversion low-titre panels. Vox Sang (1997) 0.97
Choice of Rapid HIV testing and entrance into care in Baltimore City sexually transmitted infections clinics. AIDS Patient Care STDS (2011) 0.94
A 10-minute, US Food and Drug Administration-approved HIV test. Expert Rev Mol Diagn (2005) 0.91
HIV nucleic acid amplification testing versus rapid testing: it is worth the wait. Testing preferences of men who have sex with men. J Acquir Immune Defic Syndr (2012) 0.90
Are there benefits to starting antiretroviral therapy during primary HIV infection? Conclusions from the Seattle Primary Infection Cohort vary by control group. Int J STD AIDS (2012) 0.87
Performance of Determine Combo and other point-of-care HIV tests among Seattle MSM. J Clin Virol (2016) 0.77